Daniel Ontaneda
The Cleveland Clinic
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Daniel Ontaneda as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 20:31 UTC. Open this list on ClinicalTrials.gov
- N/ANCT07424027 · Central Vein Sign in Multiple Sclerosis Extension StudyThe Cleveland Clinic · recruiting · Multiple Sclerosis · principal investigator
- N/ANCT04495556 · Central Vein Sign: a Diagnostic Biomarker in Multiple SclerosisThe Cleveland Clinic · completed · Multiple Sclerosis · principal investigator
- Ph4NCT03535298 · Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMSThe Cleveland Clinic · active not recruiting · Multiple Sclerosis, Relapsing-Remitting · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 20:31 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Susceptibility based MRI biomarkers for multiple sclerosisR56NS146394 · NINDS · CLEVELAND CLINIC LERNER COM-CWRU · fiscal years 2026 · $549,500 awarded in 2026Same name and institution; not confirmed by an ID
- Central Vein Sign: A Diagnostic Biomarker in Multiple SclerosisU01NS116776 · NINDS · CLEVELAND CLINIC LERNER COM-CWRU · fiscal years 2020 to 2024 · $1,617,384 awarded in 2024Grant number is on one of their registry trials
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 20:31 UTC. The ranking covers the 200 most relevant of 7 PubMed records, and a shared surname and initials can bring in a namesake. All 7 on PubMed
- Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.N Engl J Med · 2018230 citationsRCR 9.7
- Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.Contemp Clin Trials · 201657 citationsRCR 2.3
- Relapse rates in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of pooled data from three phase 3 trials.Mult Scler Relat Disord · 201638 citationsRCR 1.6
- 32 citationsRCR 5.7
- Identifying the start of multiple sclerosis injury: a serial DTI study.J Neuroimaging · 201426 citationsRCR 1.0
- Effect of ibudilast on thalamic magnetization transfer ratio and volume in progressive multiple sclerosis.Mult Scler · 20236 citationsRCR 0.7